Abstract #1973
Effects of Lisdexamfetamine on prefrontal brain activation, glutamate concentration and executive function in menopausal women with memory complaints: A double-blind placebo controlled crossover study at 7T
Ravi Prakash Reddy Nanga 1 , Simon Vandekar 2 , Sheila Shanmugan 2,3 , Sarah Conlin 2,3 , Kejia Cai 1 , Mark A Elliott 1 , Hari Hariharan 1 , Jeanette Bradley 2,3 , Ravinder Reddy 1 , and Neill C Epperson 2,3
1
Radiology, University of Pennsylvania,
Philadelphia, Pennsylvania, United States,
2
Psychiatry,
University of Pennsylvania, Philadelphia, Pennsylvania,
United States,
3
Penn
Center for Womens Behavioral Wellness, University of
Pennsylvania, Philadelphia, Pennsylvania, United States
Menopausal women frequently report new onset decline in
memory, focus, and organization- domains of cognition
referred to as executive functions (EFs). Loss of
estradiol effects on dopaminergic systems in the
prefrontal cortex is thought to contribute to this
phenomenon. We sought to test whether the
psychostimulant lisdexamphetamine (LDX) improves EF in
menopausal women and whether drug-induced changes in
prefrontal glutamate and neural activation (measured at
7T) are responsible for improved working memory. This is
the first study of its kind and may provide evidence to
support LDX treatment in women with EF complaints
related to natural or surgical/chemotherapy-induced
menopause.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
